Michael G.
- Country
- Germany
- Department
- Mediprojekt GbR
Research Overview
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase II Multicenter Study of Acalabrutinib in Elderly or Frail Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia
- Evaluation of Adjuvant Therapy with Capecitabine in Stage II Colon and Rectal Cancer Patients with ctDNA Positivity Post-Resection
Data & Insights
Has run more than one trial at 208 of 452 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and other blood cancers, with particular emphasis on novel therapeutic approaches and treatment optimization.
- CLL treatment strategies in elderly and frail patients
- Advanced therapies for Waldenström's Macroglobulinemia
- Hodgkin Lymphoma management
Research focus includes targeted therapies and combination treatment protocols for hematologic malignancies.
Gastrointestinal Oncology
Expertise in treating advanced gastric cancer and colorectal malignancies, with focus on innovative surgical and therapeutic approaches.
- Esophagogastric junction adenocarcinoma
- Advanced colon cancer treatment
- Rectal cancer management strategies
Specializes in perioperative treatment approaches and organ preservation techniques.
Precision Medicine
Leading research in personalized treatment approaches and biomarker-guided therapy for various cancers.
- MRD-guided treatment protocols
- High-risk cancer patient management
- Circulating tumor DNA analysis
Focus on developing risk-adapted treatment strategies and innovative therapeutic combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.